Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer
2011 · Annals of Oncology · 31 citations
https://doi.org/10.1093/annonc/mdr014
B
Beth Sherrill
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
48
Papers
1.6K
Citations
18
h-index
22
i10-index
Beth Sherrill is an academic researcher from RTI Health Solutions. The author has contributed to research in topics: Cancer Treatment and Pharmacology & Advanced Breast Cancer Therapies & HER2/EGFR in Cancer Research. The author has an h-index of 18, co-authored 41 publications.
Papers by this author
worksQ-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
2013 · British Journal of Cancer · 29 citations
https://doi.org/10.1038/bjc.2013.298
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer
2010 · Current Medical Research and Opinion · 16 citations
https://doi.org/10.1185/03007991003590860
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat